Comparative Pharmacology
Head-to-head clinical analysis: GATIFLOXACIN versus ITOVEBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GATIFLOXACIN versus ITOVEBI.
GATIFLOXACIN vs ITOVEBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gatifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication, transcription, repair, and recombination.
ITOVEBI is a monoclonal antibody that inhibits the interaction of programmed cell death protein 1 (PD-1) with its ligands PD-L1 and PD-L2, thereby enhancing T-cell-mediated antitumor immune responses.
400 mg orally or intravenously once daily
12.5 mg orally once daily
None Documented
None Documented
Terminal elimination half-life 7-14 hours (mean ~10 hours in healthy adults); prolonged in renal impairment (up to 40 hours with CrCl <30 mL/min)
Clinical Note
moderateGatifloxacin + Digoxin
"Gatifloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateGatifloxacin + Digitoxin
"Gatifloxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateGatifloxacin + Deslanoside
"Gatifloxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateGatifloxacin + Acetyldigitoxin
"Gatifloxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 12 hours in patients with normal renal function, allowing for once-daily dosing. Half-life is prolonged in renal impairment.
Primarily renal excretion (70-87% unchanged in urine) via glomerular filtration and tubular secretion; ~10% biliary/fecal
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose, with biliary/fecal elimination contributing about 30%. The remaining 10% is metabolized.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic